Novo Nordisk news and events in 2026
Novo Nordisk news, hiring, acquisitions and Reddit, Glassdoor, podcast and web signals in one place. Every row is dated and links to its source.
PublicBusiness Consulting and Services10,000+ employeesnovonordisk.comLinkedIn
- Dated updates
- 84
- Last event
- Sep 29, 2026
- Open rolesSnapshot Sep 29, 2026
- 154
Overview
Novo Nordisk by topic
154open roles
56+signals
40 in the last 90 days
- Glassdoor15+
- LinkedIn15+
- Website changes15+
- Patents5
- and 2 more sources
Latest events
Latest Novo Nordisk events
Showing 10 of 28 events. The Signal API returns all of them.
Get them with one API call- AcquisitionNovo Nordisk agrees to buy Chinese weight-loss pill for 2.5 billion eurosWith Jiangsu Hengrui Pharmaceuticals
- PartnershipNovo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596Novo Nordisk has entered into an exclusive license agreement with Hengrui Pharma for HRS-1596, a phase 1-ready GLP-1/GIP dual receptor agonist, in a deal potentially worth up to $2.6 billion.
- InvestmentNovo Nordisk A/S - share repurchase programmeNovo Nordisk reported further purchases of its own B shares as part of its ongoing buyback program.
- PartnershipNovo Nordisk Stock: License Deal with Nanexa SealedNovo Nordisk has entered into a worldwide license agreement with Swedish specialist Nanexa to gain access to its proprietary PharmaShell technology for delayed drug release, a deal potentially worth up to 1.165 billion euros.
- InvestmentNovo and UNICEF expand partnership to support a healthier start for more than 80 million childrenNovo Nordisk is committing USD 18 million from 2026 to 2030 to a partnership with UNICEF to advance evidence-based policies and prevention services for childhood obesity in seven priority countries.
- PartnershipNovo Nordisk Stock: CagriSema beats Eli Lilly drug$18M · With UNICEF · 2 stories
- NewsNovo acquires three early-stage obesity programs from Columbia-linked KallyopeNovo Nordisk has agreed to acquire three early-stage obesity drug programs from New York-based Kallyope, Inc.
- Investment
- In development
- In developmentNovo’s once-weekly Sogroya® (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness)Novo Nordisk's once-weekly growth hormone treatment, Sogroya® (somapacitan), received a positive opinion from the European Medicines Agency's CHMP, recommending it for children with idiopathic short stature.
Showing 10 of 28 events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Novo Nordisk with the Signal API
One POST /v1/companies/enrich call with novonordisk.com returns every signal type for Novo Nordisk, each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"novonordisk.com","limit":20}'Same industry
Companies related to Novo Nordisk
Novo Nordisk questions
What is the latest news on Novo Nordisk?
What is going on with Novo Nordisk?
Has Novo Nordisk announced any acquisitions?
What else does Autobound track for Novo Nordisk?
Is Novo Nordisk hiring right now?
Source. News, SEC filings (8-K, 10-K, 10-Q, Form D), hiring data and other signals (Reddit, podcasts, Glassdoor, reviews, social posts, patents, web traffic) from the Autobound Signal API.
Method. Stories are grouped when they report the same event within 14 days. Rows that do not name the company are removed. Each row links its source.
Data as of .